| [1] |
SHI Yingzi, ZHAO Yang.
Impact of China-US drug regulatory incentives on local innovative drug simultaneous development in multiple countries: An empirical study based on zanubrutinib
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 560-569.
|
| [2] |
JIANG Haihong, LI Xiao, LIU Yang.
Four dimensions of receiving overseas clinical trial data about drug and medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 835-840.
|
| [3] |
LI Hao, CHENG Juan, ZHENG Xiaoqing, ZHANG Lei, ZHU Na, ZHOU Chengyue, WU Jian.
Establishment and application of DUE criteria for IV administration of voriconazole
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1420-1424.
|
| [4] |
ZHANG Jian-ping, LOU Xiao-jie, ZHOU Yu-sheng.
Beijing anti-AIDS drug clinical trial case and particular protection to vulnerable persons as subjects
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 832-836.
|
| [5] |
WANG Xiu-qin, XIONG Ning-ning, LIU Shen-lin, LI Qi-yi, JIANG Meng, LIU Fang, ZOU Jian-dong, GAO Wei-min, XUE Xue-kun.
Ethic review in clinical research:persons who are serving a sentence or receiving reeducation through labour
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(7): 837-840.
|
| [6] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(1): 55-57.
|
| [7] |
BO Qing-yan, XIONG Ning-ning, ZOU Jian-dong, JIANG Meng, LIU Fang, Anna Zhao-Wong.
Internationally agreed medical terminology :Medical Dictionary for Regulatory Activities
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 586-590.
|
